251 related articles for article (PubMed ID: 26113580)
21. Recurrence dynamics of breast cancer according to baseline body mass index.
Biganzoli E; Desmedt C; Fornili M; de Azambuja E; Cornez N; Ries F; Closon-Dejardin MT; Kerger J; Focan C; Di Leo A; Nogaret JM; Sotiriou C; Piccart M; Demicheli R
Eur J Cancer; 2017 Dec; 87():10-20. PubMed ID: 29096156
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
23. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
[TBL] [Abstract][Full Text] [Related]
24. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
Henderson IC; Berry DA; Demetri GD; Cirrincione CT; Goldstein LJ; Martino S; Ingle JN; Cooper MR; Hayes DF; Tkaczuk KH; Fleming G; Holland JF; Duggan DB; Carpenter JT; Frei E; Schilsky RL; Wood WC; Muss HB; Norton L
J Clin Oncol; 2003 Mar; 21(6):976-83. PubMed ID: 12637460
[TBL] [Abstract][Full Text] [Related]
25. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).
Boughey JC; Ballman KV; McCall LM; Mittendorf EA; Symmans WF; Julian TB; Byrd D; Hunt KK
Ann Surg; 2017 Oct; 266(4):667-676. PubMed ID: 28657941
[TBL] [Abstract][Full Text] [Related]
26. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Liu S; Chapman JA; Burnell MJ; Levine MN; Pritchard KI; Whelan TJ; Rugo HS; Albain KS; Perez EA; Virk S; Barry G; Gao D; O'Brien P; Shepherd LE; Nielsen TO; Gelmon KA
Breast Cancer Res Treat; 2015 Jan; 149(2):439-48. PubMed ID: 25552364
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer.
Yazilitas D; Sendur MA; Karaca H; Ozdemir N; Aksoy S; Berk V; Yazici O; Ozturk B; Ozkan M; Zengin N; Altundag K
Asian Pac J Cancer Prev; 2015; 16(4):1471-7. PubMed ID: 25743817
[TBL] [Abstract][Full Text] [Related]
29. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B
Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900
[TBL] [Abstract][Full Text] [Related]
30. Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer.
Silvestrini R; Luisi A; Zambetti M; Cipriani S; Valagussa P; Bonadonna G; Daidone MG
Int J Cancer; 2000 Aug; 87(3):405-11. PubMed ID: 10897047
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
Mamounas EP; Bryant J; Lembersky B; Fehrenbacher L; Sedlacek SM; Fisher B; Wickerham DL; Yothers G; Soran A; Wolmark N
J Clin Oncol; 2005 Jun; 23(16):3686-96. PubMed ID: 15897552
[TBL] [Abstract][Full Text] [Related]
32. Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.
Kogawa T; Fujii T; Fouad TM; Liu DD; Harano K; Masuda H; Iwase T; Barnett C; Park YS; Lim B; Tripathy D; Litton JK; Ueno NT
Breast Cancer Res Treat; 2018 Sep; 171(2):501-511. PubMed ID: 29915946
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of preoperative
Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
[TBL] [Abstract][Full Text] [Related]
34. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
35. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
J BUON; 2013; 18(2):335-41. PubMed ID: 23818343
[TBL] [Abstract][Full Text] [Related]
36. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
37. Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.
; Colleoni M; Gelber S; Simoncini E; Pagani O; Gelber RD; Price KN; Castiglione-Gertsch M; Coates AS; Goldhirsch A
Ann Oncol; 2007 Jul; 18(7):1177-84. PubMed ID: 17429101
[TBL] [Abstract][Full Text] [Related]
38. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
[TBL] [Abstract][Full Text] [Related]
39. Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer.
Nguyen D; Yu J; Reinhold WC; Yang SX
JAMA Netw Open; 2020 Jul; 3(7):e207213. PubMed ID: 32644137
[TBL] [Abstract][Full Text] [Related]
40. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.
Perez EA; Ballman KV; Mashadi-Hossein A; Tenner KS; Kachergus JM; Norton N; Necela BM; Carr JM; Ferree S; Perou CM; Baehner F; Cheang MC; Thompson EA
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27794124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
